{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042982","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.695705+00:00","generated_at":"2026-05-21T07:57:41.621277+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024","bullets":["Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.","FY2024 revenue increased 234% YoY; operating expenses reduced 21%; EPS improved 77%.","Secured three licensing partnerships with potential $7M upfront and up to $660M in milestones.","Received approximately $0.5M in upfront payments in FY2025 year-to-date.","Preliminary discussions underway with pharma and AI firms for co-developing Phase III-ready MDD and ADHD candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042982","json":"https://secwatch.observer/filing/0001213900-25-042982.json","markdown":"https://secwatch.observer/filing/0001213900-25-042982.md","text":"https://secwatch.observer/filing/0001213900-25-042982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025042982/0001213900-25-042982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025042982/ea0242092-8ka1_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T07:57:41.621277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}